Oncolytics Biotech Inc
TSX:ONC

Watchlist Manager
Oncolytics Biotech Inc Logo
Oncolytics Biotech Inc
TSX:ONC
Watchlist
Price: 14.9 CAD -1.32% Market Closed
Market Cap: 173.1m CAD

Oncolytics Biotech Inc
Net Issuance of Debt

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Oncolytics Biotech Inc
Net Issuance of Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Debt CAGR 3Y CAGR 5Y CAGR 10Y
Oncolytics Biotech Inc
TSX:ONC
Net Issuance of Debt
-CA$385k
CAGR 3-Years
-4%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Net Issuance of Debt
-$17.8m
CAGR 3-Years
-47%
CAGR 5-Years
-36%
CAGR 10-Years
-43%
Repare Therapeutics Inc
NASDAQ:RPTX
Net Issuance of Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Net Issuance of Debt
-$12.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Net Issuance of Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Spectral Medical Inc
TSX:EDT
Net Issuance of Debt
CA$9.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Oncolytics Biotech Inc
Glance View

Market Cap
173.1m CAD
Industry
Biotechnology

Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta and currently employs 26 full-time employees. The company went IPO on 2000-06-01. The firm is focused on the discovery and development of pharmaceutical products for the treatment of cancers. Its lead product, Pelareorep, is a systemically administered immuno-oncology (I-O) viral agent with the potential to treat a variety of cancers. Pelareorep’s anti-tumor activity is based on three modes: selective viral replication in permissive cancer cells, which leads to tumor cell lysis; activation of innate immunity in response to the infection, which results in a cascade of chemokines/cytokines, causing natural killer (NK) cells to be activated and attack cancer cells; and specific adaptive immune response triggered by tumor and viral-associated antigens displayed by antigen presenting cells (APCs), infected tumor cells and dendritic cells to T cells.

ONC Intrinsic Value
Not Available

See Also

What is Oncolytics Biotech Inc's Net Issuance of Debt?
Net Issuance of Debt
-385k CAD

Based on the financial report for Jun 30, 2025, Oncolytics Biotech Inc's Net Issuance of Debt amounts to -385k CAD.

What is Oncolytics Biotech Inc's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 5Y
3%

Over the last year, the Net Issuance of Debt growth was -3%. The average annual Net Issuance of Debt growth rates for Oncolytics Biotech Inc have been -4% over the past three years , 3% over the past five years .

Back to Top